Hormones News and Research

RSS

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

Adult weight gain strongly linked to higher obesity-related cancer risk

New research presented at this year's European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that people who gain the highest amount of weight across adulthood are at greatly increased risk of certain obesity related cancers.

13 May 2026

Global effort redefines the most common hormonal disorder in women

A global effort led by Monash University has changed the name of a significant women's health condition that was misunderstood to be 'all about ovarian cysts'.

13 May 2026

Maternal insulin resistance linked to higher abdominal fat in girls

Girls born to mothers with higher insulin resistance during the third trimester are more likely to have more abdominal fat at age 7, according to research presented at the 28th European Congress of Endocrinology in Prague.

12 May 2026

Study links metabolic dysfunction to cognitive impairment in bipolar disorder

While they share similar depressive and cognitive symptoms, the biological underpinnings of bipolar disorder and major depressive disorder are distinct.

11 May 2026

Infant exposure to environmental chemicals linked to lower bone density

Infants exposed to certain environmental chemicals, including breast milk and everyday products such as personal care items, are more likely to have lower bone density in the first year of their lives, according to research presented at the 28th European Congress of Endocrinology in Prague.

11 May 2026

Diabetes, weight-loss drugs not a perfect fit?

Type 2 diabetes affects millions of people worldwide and now a new international study, jointly led by Adelaide University, University of Oxford, ETH Zurich, and Stanford University, has found one in ten people may not be benefiting from common medications used to treat the condition.

11 May 2026

Prenatal progesterone exposure alters brain development genes in male fetuses

Excessive exposure to progesterone in the womb can alter a gene in the frontal cortex in male sheep fetuses, which is needed for brain development and function, according to research presented at the 28th European Congress of Endocrinology in Prague.

11 May 2026

Study challenges assumptions about testosterone’s role in brain cancer

Scientists have long suspected that androgens, male sex hormones like testosterone, may help tumors grow because the hormones can suppress immune responses to some cancers.

8 May 2026

AI-driven hormone tracking could help detect infertility early and improve conception

Men and women who appear hormonally 'normal' may still have undetected disruptions in the timing and coordination of their reproductive hormones that could impair fertility, according to research presented at the 28th European Congress of Endocrinology in Prague.

8 May 2026

Study reveals why women face higher autoimmune disease risks

Ahead of World Lupus Day on May 10, new research from the Garvan Institute of Medical Research and UNSW Sydney helps explain why women are significantly more likely to be diagnosed with an autoimmune disease – a condition where the immune system misfires and mistakenly attacks the body's own healthy tissues.

7 May 2026

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Menopause symptoms like hot flushes can be debilitating. Dr. Katie Barber highlights new treatments, including fezolinetant, for improved patient care.

7 May 2026

Testosterone may help limit brain tumor growth in men

In a new National Institutes of Health (NIH)-funded study, scientists at Cleveland Clinic discovered that hormones associated with male development may play a key role in limiting the growth of brain tumors in men.

6 May 2026

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial.

6 May 2026

New method matures lab-grown heart cells for better research

Researchers at the University of Toronto's Institute of Biomedical Engineering have developed a new method to mature lab-grown heart cells, so they more closely resemble adult human heart tissue.

5 May 2026

Obesity and Alzheimer’s linked through early metabolic disruptions

By 2030, the population in the United States aged 65 and older is expected to reach 71 million or about 20% of Americans. This growth is likely to increase the burden of age-related diseases, particularly Alzheimer's disease (AD), affecting about 1 in 9 adults over 65.

5 May 2026

Protective brain pathway may slow Parkinson’s progression in females

Scientists have identified a protective brain pathway that may help slow the progression of Parkinson's disease by strengthening the brain's own dopamine‑producing neurons, but the positive effect was only observed in females.

4 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026

New research identifies stress response as trigger for heart inflammation

After a heart attack, the body rapidly floods the injured heart with neutrophils - white blood cells that help repair damage but can also make it worse when too many arrive too quickly.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026